(RTTNews) - Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies ...

Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

@article{sequence, author = {Xiaoliang Wu and Alexander Kolar and Joaquin Chung and Dong Jin and Tian Zhong and Rajkumar Kettimuthu and Martin Suchara}, title = {SeQUeNCe: a customizable ...

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation ...